The IL4R Knockout ACHN Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the IL4R gene in the ACHN human renal cell adenocarcinoma line. This genetically heterogeneous loss-of-function model abolishes expression of the interleukin-4 receptor alpha chain, enabling robust dissection of IL-4 and IL-13 signaling without the confounding effects of clonal variation. The polyclonal format captures diverse editing events across the population, making it well-suited for bulk functional assays and screens where population-level responses reflect native cellular heterogeneity.
Derived from a malignant pleural effusion, the parental ACHN cell line is a widely used model of renal epithelial adenocarcinoma that retains key kidney epithelial characteristics. It is extensively employed in studies of renal cancer biology, drug resistance, and tumor-stroma interactions. The clinically relevant oncogenic background of ACHN cells provides an appropriate platform for interrogating the tumor-intrinsic roles of cytokine receptors, and the IL4R knockout background specifically permits elucidation of how IL-4 receptor signaling contributes to malignant phenotypes such as proliferation and immune evasion.
IL4R encodes the ligand-binding subunit of the interleukin-4 receptor, which heterodimerizes with IL2RG to form the type I receptor or with IL13RA1 to form the type II receptor, subsequently activating receptor-associated Janus kinases JAK1 and JAK3. This triggers STAT6 phosphorylation, dimerization, and nuclear translocation, driving transcription of Th2-associated targets including GATA3 and the chemokines CCL17, CCL22, and CCL26. Signaling is initiated by upstream cytokines IL-4 and IL-13 and modulated by IL-2, while adaptors IRS1 and IRS2 link to alternative pathways. Feedback regulators such as SOCS1 further tune the response, placing IL4R at a central node of cytokine-cytokine receptor interaction and JAK-STAT networks.
In renal cell carcinoma, IL4R signaling can exhibit context-dependent effects, potentially promoting tumor progression through Th2-skewed immune microenvironments or direct modulation of tumor cell survival and invasiveness. This knockout model allows precise dissection of these roles by comparing STAT6 phosphorylation, chemokine expression, and functional responses to IL-4 or IL-13 stimulation between wild-type and IL4R-null ACHN populations, all while preserving the native cellular background without clonal artifacts. It thereby provides a clean experimental system for defining how IL4R-driven signals influence renal cancer cell biology and immune crosstalk.
Typical research applications include screening for modulators of Th2 differentiation, evaluating drug sensitivity in an IL4R-null context, and investigating the contribution of IL-4/IL-13 signaling to renal tumor biology. The cells are amenable to Western blotting for IL4R and phospho-STAT6, RT-qPCR for transcript quantification, flow cytometric analysis of surface receptor expression, and ELISA-based detection of downstream factors like CCL17. Additional functional assays such as cell proliferation and migration provide comprehensive phenotypic readouts. This polyclonal knockout population serves as a robust platform for mechanistic studies and drug discovery efforts targeting the IL-4/IL-13 axis. For further technical details, contact Ascent Research.
